Related Experiment Video
Updated: Feb 2, 2026

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis
Published on: December 15, 2011
Renal Cell Carcinoma Is Abrogated by p53 Stabilization through Transglutaminase 2 Inhibition
Seon-Hyeong Lee1, Won-Kyu Lee2,3, Nayeon Kim4,5
1Tumor Microenvironment Research Branch, Division of Cancer Biology, National Cancer Center, Goyang, Gyeonggi-do 10408, Korea. shlee1987@gmail.com.
Abstract:
In general, expression of transglutaminase 2 (TGase 2) is upregulated in renal cell carcinoma (RCC), resulting in p53 instability. Previous studies show that TGase 2 binds to p53 and transports it to the autophagosome. Knockdown or inhibition of TGase 2 in RCC induces p53-mediated apoptosis. Here, we screened a chemical library for TGase 2 inhibitors and identified streptonigrin as a potential therapeutic compound for RCC. Surface plasmon resonance and mass spectroscopy were used to measure streptonigrin binding to TGase 2. Mass spectrometry analysis revealed that streptonigrin binds to the N-terminus of TGase 2 (amino acids 95⁻116), which is associated with inhibition of TGase 2 activity in vitro and with p53 stabilization in RCC. The anti-cancer effects of streptonigrin on RCC cell lines were demonstrated in cell proliferation and cell death assays. In addition, a single dose of streptonigrin (0.2 mg/kg) showed marked anti-tumor effects in a preclinical RCC model by stabilizing p53. Inhibition of TGase 2 using streptonigrin increased p53 stability, which resulted in p53-mediated apoptosis of RCC. Thus, targeting TGase 2 may be a new therapeutic approach to RCC.
Insights
Streptonigrin inhibits transglutaminase 2 (TGase 2) in renal cell carcinoma (RCC), stabilizing p53 and inducing cancer cell death. This suggests targeting TGase 2 is a promising therapeutic strategy for RCC.
Area of Science:
- Oncology
- Biochemistry
- Molecular Biology
Background:
- Transglutaminase 2 (TGase 2) is upregulated in renal cell carcinoma (RCC), leading to p53 instability.
- TGase 2 binds to and facilitates the degradation of p53 in RCC.
- Inhibiting TGase 2 promotes p53-mediated apoptosis in RCC.
Purpose of the Study:
- To identify TGase 2 inhibitors for potential RCC therapy.
- To investigate the therapeutic potential of streptonigrin in RCC.
Main Methods:
- Screening a chemical library for TGase 2 inhibitors.
- Surface plasmon resonance and mass spectrometry to confirm streptonigrin-TGase 2 binding.
- In vitro and in vivo assays to evaluate streptonigrin's anti-cancer effects in RCC models.
Main Results:
- Streptonigrin was identified as a TGase 2 inhibitor.
- Streptonigrin binds to TGase 2 at amino acids 95-116, inhibiting its activity and stabilizing p53.
- Streptonigrin demonstrated anti-cancer effects in RCC cell lines and a preclinical RCC model.
Conclusions:
- Targeting TGase 2 with streptonigrin represents a novel therapeutic strategy for RCC.
- Streptonigrin's ability to stabilize p53 and induce apoptosis offers a new avenue for RCC treatment.
More Related Videos
Related Concept Videos
Feedback Inhibition
Nuclear Stability
To hold positively charged protons together...
RNA Stability
Stability
The stability of an LTI system is determined by the roots of its characteristic equation, known as poles. A system is stable if it produces a bounded...
Factors Affecting Renal Clearance: Renal Impairment
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
Enzyme Inhibition

